Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 5/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275185 | 0.94 | FGFR1 (0.36) | FGFR1FGFR3IGF1RPPARGPPARA | |
| SCHEMBL2265089 | 0.91 | ACVR1 (0.33) | IGF1RPPARGPPARAMETSLC5A1 | |
| SCHEMBL2364945 | 0.91 | FGFR1 (0.39) | FGFR1FGFR3PPARGPPARAIRAK4 | |
| SCHEMBL2265508 | 0.87 | MET (0.34) | FGFR3IGF1RPPARGPPARAMET | |
| SCHEMBL12516412 | 0.85 | FGFR1 (0.41) | FGFR1FGFR3IRAK4 | |
| SCHEMBL2348920 | 0.85 | GPR84 (0.41) | PPARGIRAK4MET | |
| SCHEMBL13449337 | 0.85 | HSD17B13 (0.39) | IGF1RPPARGPPARAMET | |
| SCHEMBL2222323 | 0.85 | IRAK1 (0.35) | METSLC5A1 | |
| SCHEMBL2222170 | 0.85 | IRAK1 (0.40) | IGF1RPPARGPPARAIRAK4MET | |
| SCHEMBL2362911 | 0.85 | IRAK4 (0.37) | IGF1RPPARGPPARAIRAK4MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | FGFR1 41/4885FGFR3 124/4885IGF1R 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.